Search Results
Jul 14, 2026, 08:00 ET Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
Accordingly, if successful, these trials will support the submission of a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) for regulatory approval in Europe. The trial design not only allows determination of ibezapolstat's ability to achieve Clinical Cure of CDI as measured
More news about: Acurx Pharmaceuticals, Inc.
Jul 09, 2026, 19:57 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)." Specifically, the press release
More news about: Pomerantz LLP
Jul 09, 2026, 09:00 ET Merrill Managed Account Advisors Surpasses $1 Trillion, Celebrates 20 Years of Innovation
inception, MAA has been an industry leader in innovation in managed solutions. MAA was among the first to transition separately managed accounts (SMAs) to model-based delivery and among the first to launch custom-managed strategies, enabling advisors to build tailored, multi-sleeve portfolios. MAA capabilities
More news about: Bank of America Corporation
Jul 08, 2026, 14:42 ET Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Jul 08, 2026, 14:24 ET Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Jul 02, 2026, 14:41 ET Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Jul 02, 2026, 14:17 ET Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It
More news about: Northwest Biotherapeutics, Inc.
Jul 01, 2026, 20:11 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)." Specifically, the press release
More news about: Pomerantz LLP
Jul 01, 2026, 16:48 ET MAA Announces Date of Second Quarter 2026 Earnings Release, Conference Call
GERMANTOWN, Tenn., July 1, 2026 /PRNewswire/ -- MAA (NYSE: MAA) announced today that the Company expects to release its second quarter 2026 results on Wednesday, July 29, 2026, after market close and will hold a conference
More news about: MAA
Jun 29, 2026, 12:00 ET Frontage Laboratories Is Pleased to Welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services
assessment, including transporter and enzyme‑mediated pathwaysRegulatory submissions, with emphasis on IND, NDA, and MAA clinical pharmacology packagesDr. Prakash previously held several academic appointments at Vanderbilt and University of Maryland
More news about: Frontage Laboratories, Inc.
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has validated the Marketing Authorisation Application (MAA) submitted by its partner Eisai Co, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), for taletrectinib for the treatment of advanced ROS1-positive
More news about: Nuvation Bio Inc.
Jun 25, 2026, 10:31 ET Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight
Meeting with the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) and intends to file a Marketing Authorization Application (MAA) for AMT-130 as a treatment for Huntington's disease in the third quarter of 2026.In April 2026, PTC Therapeutics, Inc. announced positive
More news about: DelveInsight Business Research, LLP
Jun 24, 2026, 08:47 ET Parks Associates Announces Agenda and Speakers for Fourth Annual Smart Spaces on September 15-16 in Plano, Texas
Co-founder and CEO, AppWorkDave Lillis, CEO, DOORSean Miller, Chief Revenue Officer, Lessen LLCJosh Siddon, VP, IT Architecture, MAA – Mid America Apartment CompanyTodd Thorpe, Director of Business Development, Cambium NetworksMariam Walker, Sr. Director Community
More news about: Parks Associates
Jun 22, 2026, 16:10 ET RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions, the risk that the MAA submission for Talicia may not be approved; the risk that the Company will not succeed in its enforcement action against Kukbo, and if successful may
More news about: RedHill Biopharma Ltd.
Jun 20, 2026, 02:30 ET Reliance Digital Launches 'Baaptaa', a Father's Day Campaign Celebrating the Many Expressions of Fatherhood
Digital has launched 'Baaptaa', a Father's Day campaign to celebrate the many expressions of fatherhood. Built around a simple cultural observation, while "Maa ki Mamta" has long been a part of India's collective vocabulary, there has never been a word that captures the distinct ways fathers express love, the
More news about: Reliance Digital
Jun 18, 2026, 08:00 ET RedHill Biopharma Announces Up To $19.4 Million Private Placement
implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions, the risk that the MAA submission for Talicia may not be approved; the risk that the Company will not succeed in its enforcement action against Kukbo, and if successful may
More news about: RedHill Biopharma Ltd.
Jun 16, 2026, 08:00 ET Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details
More news about: Acurx Pharmaceuticals, Inc.
Jun 10, 2026, 20:59 ET GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8
in Japan). The company expects to finalize the clinical study report by the end of September, followed by a drug approval application in Japan. Japan MAA submission expected in third quarter 2026. An application for marketing authorization in Taiwan is scheduled for next year, with a target launch date
More news about: GlycoNex, Inc.
Jun 02, 2026, 08:33 ET Discover MGallery Collection's Debut in the Maldives, the V Villas Maldives at Mirihi - MGallery Collection
blue—and the Akoya Sea Lounge, which features a dramatic, hovering rope chandelier. For groups seeking ultimate seclusion, the Mirihi Maa, the resort's signature suite, offers expansive indoor-outdoor living with a private pool and direct access to the lagoonA Culinary Symphony
More news about: MGallery Hotel Collection
Jun 01, 2026, 16:15 ET MAA to Present at the Nareit REITweek: 2026 Investor Conference
Company's website at www.maac.com.About MAAMAA is a self-administered real estate investment trust (REIT) and member of the S&P 500. MAA owns or has ownership interest in apartment communities primarily throughout the Southeast, Southwest
More news about: MAA
Jun 01, 2026, 16:15 ET MAA Announces Regular Quarterly Preferred Dividend
About MAAMAA is a self-administered real estate investment trust (REIT) and member of the S&P 500. MAA owns or has ownership interest in apartment communities primarily throughout the Southeast, Southwest
More news about: MAA
Jun 01, 2026, 08:00 ET Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
sites.ZAYNICH was approved by the Drugs Controller General of India (DCGI) on May 27, 2026. Wockhardt has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency.About ZAYNICH™ (cefepime and zidebactam) for InjectionZAYNICH™ (cefepime
More news about: Wockhardt
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
DOVBLERON®. Additionally, Nuvation Bio, along with its partner Eisai, announced in March 2026 that the Marketing Authorisation Application (MAA) for taletrectinib was validated by the European Medicines Agency for full approval consideration with a standard review timeline.A separate "Trial
More news about: Nuvation Bio Inc.
May 26, 2026, 12:35 ET DIRECTV Financing, LLC and DIRECTV Financing Co-Obligor, Inc. Announce Consideration for Tender Offer for Up to $1,400,000,000 in Aggregate Principal Amount of Their 5.875% Senior Secured Notes Due 2027
(1)25461L AA0 /US25461LAA08U2541M AA8 / USU2541MAA81$1,711,000,000
More news about: DirecTV
May 26, 2026, 08:06 ET DIRECTV Financing, LLC and DIRECTV Financing Co-Obligor, Inc. Announce Early Results of Cash Tender Offer for 5.875% Senior Secured Notes Due 2027
25461L AA0 / US25461LAA08 U2541M AA8 / USU2541MAA81$1,711,000,000
More news about: DIRECTV Financing, LLC and DIRECTV Financing Co-Obligor, Inc.